An insight into zolpidem abuse and dependence
DOI:
https://doi.org/10.12775/JEHS.2023.13.03.033Keywords
zolpidem, z-drugs, abuse, misuseAbstract
Background: Z-drugs (zopiclone, zaleplon, and zolpidem) are commonly prescribed medicine classes associated with a risk of abuse, dependence or withdrawal.
Objective: The purpose of our work is to review the current knowledge on the evidence for z-drugs harms and estimate the prevalence of dispensed prescriptions.
Material and Methods: A literature review was conducted in PubMed database using the key words: “Zolpidem”, “Z-drugs”, “Abuse”, “Dependence”
Results: According to our findings, zolpidem should be prescribed with the same caution as BZDs, especially in patients with a history of drug abuse or in the elderly.
Conclusion: Psychiatrists and physicians should be aware of the misuse potential of zolpidem and adopt measures restricting its use.
References
Marsden J, White M, Annand F, Burkinshaw P, Carville S, Eastwood B, Kelleher M, Knight J, O'Connor R, Tran A, Willey P, Greaves F, Taylor S. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England. Lancet Psychiatry. 2019 Nov;6(11):935-950.
Orsolini L, Chiappini S, Grandinetti P, Bruschi A, Testa R, Provenzano A, Berardis D, Volpe U. 'Z-trip'? A Comprehensive Overview and a Case-series of Zolpidem Misuse. Clin Psychopharmacol Neurosci. 2021 May 31;19(2):367-387.
Davies J, Rae TC, Montagu L. Long-term benzodiazepine and Z-drugs use in England: a survey of general practice [corrected]. Br J Gen Pract. 2017 Sep;67(662):e609-e613.
Edinoff AN, Wu N, Ghaffar YT, Prejean R, Gremillion R, Cogburn M, Chami AA, Kaye AM, Kaye AD. Zolpidem: Efficacy and Side Effects for Insomnia. Health Psychol Res. 2021 Jun 18;9(1):24927
Drover D, Lemmens H, Naidu S, Cevallos W, Darwish M, Stanski D. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther. 2000 Dec;22(12):1443-61.
Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995 Sep;29(3):142-53.
Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Jang CG, Lee SY, Lee YJ. The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res. 2018 Sep;41(9):931-936.
Chiaro G, Castelnovo A, Bianco G, Maffei P, Manconi M. Severe Chronic Abuse of Zolpidem in Refractory Insomnia. J Clin Sleep Med. 2018 Jul 15;14(7):1257-1259.
Schifano F, Chiappini S, Corkery JM, Guirguis A. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019 Apr 1;22(4):270-277.
Mahoney JE, Webb MJ, Gray SL. Zolpidem prescribing and adverse drug reactions in hospitalized general medicine patients at a Veterans Affairs hospital. Am J Geriatr Pharmacother. 2004 Mar;2(1):66-74.
McMahon M. Zolpidem, Complex Sleep-Related Behaviour and Volition. J Law Med. 2016;24(2):455-77.
Westermeyer J, Carr TM. Zolpidem-Associated Consequences: An Updated Literature Review With Case Reports. J Nerv Ment Dis. 2020 Jan;208(1):28-32.
Wong CK, Marshall NS, Grunstein RR, Ho SS, Fois RA, Hibbs DE, Hanrahan JR, Saini B. Spontaneous Adverse Event Reports Associated with Zolpidem in the United States 2003-2012. J Clin Sleep Med. 2017 Feb 15;13(2):223-234
Sabe M, Kashef H, Gironi C, Sentissi O. Zolpidem stimulant effect: Induced mania case report and systematic review of cases. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109643.
Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol. 2007 Aug;64(2):198-209.
Hockenhull J, Black JC, Haynes CM, Rockhill K, Dargan PI, Dart RC, Wood DM. Nonmedical use of benzodiazepines and Z-drugs in the UK. Br J Clin Pharmacol. 2021 Apr;87(4):1676-1683..
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Kinga Świąder, Ewa Szymańska, Sandra Ostaszewska, Kinga Augustynowicz, Jakub Chrzanowski, Jan Łoginoff, Przemysław Morawski, Zuzanna Popińska, Filip Pactwa
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 875
Number of citations: 0
